Insulet Co. (NASDAQ:PODD) – Stock analysts at Oppenheimer decreased their Q4 2018 earnings estimates for shares of Insulet in a research report issued to clients and investors on Friday, May 4th. Oppenheimer analyst S. Lichtman now forecasts that the medical instruments supplier will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.05. Oppenheimer has a “Hold” rating and a $90.00 price objective on the stock. Oppenheimer also issued estimates for Insulet’s FY2019 earnings at $0.35 EPS.
Get Insulet alerts:
A number of other equities research analysts have also recently commented on PODD. UBS raised shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Monday, January 8th. Raymond James raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Monday, January 8th. Zacks Investment Research cut shares of Insulet from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. BidaskClub raised shares of Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Barclays reaffirmed an “overweight” rating and set a $90.00 price target (up from $85.00) on shares of Insulet in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $82.26.
Shares of NASDAQ PODD opened at $83.88 on Monday. The stock has a market capitalization of $4,922.50, a P/E ratio of -182.35 and a beta of 1.39. Insulet has a 52 week low of $38.43 and a 52 week high of $94.25. The company has a debt-to-equity ratio of 3.57, a quick ratio of 5.85 and a current ratio of 6.24.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.08. The firm had revenue of $123.60 million for the quarter, compared to analysts’ expectations of $121.76 million. Insulet had a negative net margin of 4.82% and a negative return on equity of 23.62%. The firm’s revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) EPS.
Hedge funds have recently made changes to their positions in the company. Cerebellum GP LLC purchased a new position in shares of Insulet during the 4th quarter worth about $122,000. Equitec Specialists LLC purchased a new position in shares of Insulet during the 4th quarter worth about $145,000. James Hambro & Partners purchased a new position in shares of Insulet during the 4th quarter worth about $165,000. C M Bidwell & Associates Ltd. purchased a new position in shares of Insulet during the 4th quarter worth about $188,000. Finally, Zeke Capital Advisors LLC purchased a new position in shares of Insulet during the 1st quarter worth about $241,000.
In other news, COO Shacey Petrovic sold 1,319 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David A. Lemoine sold 641 shares of the stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total transaction of $49,235.21. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,884 shares of company stock worth $2,504,803. Insiders own 3.60% of the company’s stock.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.